Growth Metrics

bioAffinity Technologies (BIAF) Consolidated Net Income (2021 - 2026)

bioAffinity Technologies has reported Consolidated Net Income over the past 5 years, most recently at -$3.6 million for Q1 2026.

  • Quarterly Consolidated Net Income fell 36.47% to -$3.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$15.9 million through Mar 2026, down 63.06% year-over-year, with the annual reading at -$14.9 million for FY2025, 64.93% down from the prior year.
  • Consolidated Net Income was -$3.6 million for Q1 2026 at bioAffinity Technologies, down from -$3.1 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at -$88052.0 in Q2 2022 and troughed at -$5.1 million in Q3 2025.
  • The 5-year median for Consolidated Net Income is -$2.3 million (2023), against an average of -$2.6 million.
  • The largest YoY upside for Consolidated Net Income was 53.43% in 2023 against a maximum downside of 1876.3% in 2023.
  • A 5-year view of Consolidated Net Income shows it stood at -$1.7 million in 2022, then crashed by 41.72% to -$2.4 million in 2023, then fell by 25.02% to -$3.0 million in 2024, then fell by 5.75% to -$3.1 million in 2025, then decreased by 15.72% to -$3.6 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Consolidated Net Income are -$3.6 million (Q1 2026), -$3.1 million (Q4 2025), and -$5.1 million (Q3 2025).